NCT02392871View on ClinicalTrials.gov

Radiotherapy & Combi in Metastatic Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 23, 2019

Study Completion Date

April 17, 2020

Conditions
Metastatic Melanoma
Interventions
RADIATION

Palliative radiotherapy

DRUG

Dabrafenib and trametinib (combination)

Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.

Trial Locations (3)

2010

St Vincent's Hospital, Darlinghurst

2145

Westmead Hospital, Sydney

4102

Princess Alexandra Hospital, Brisbane

All Listed Sponsors
collaborator

Melanoma Institute Australia

OTHER

lead

Melanoma and Skin Cancer Trials Limited

OTHER

NCT02392871 - Radiotherapy & Combi in Metastatic Melanoma | Biotech Hunter | Biotech Hunter